Skip to content
HowShorted

Fate Therapeutics, Inc. short interest in 2020

In 2020, Fate Therapeutics, Inc.'s disclosed short interest ran from 12.66% of shares outstanding on 15 Jan 2020 to 12.66% on 31 Dec 2020, a change of +0.00 percentage points. The year's high was 17.13% on 15 Oct 2020 and its low 12.63% on 31 Jan 2020, averaging 14.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.86 days on 31 Aug 2020. Full history: Fate Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fate Therapeutics, Inc. in 2020

2020 in figures

Start of year
12.66% (15 Jan 2020)
End of year
12.66% (31 Dec 2020)
Change
+0.00 pp
High
17.13% (15 Oct 2020)
Low
12.63% (31 Jan 2020)
Average
14.92%
Highest days to cover
25.86 (31 Aug 2020)
SEC filings marked
8

Every report in 2020

Fate Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202012.66%8.71
31 Jan 202012.63%12.50
14 Feb 202012.81%15.40
28 Feb 202013.40%10.33
13 Mar 202013.73%7.8010-K filed, results (8-K)
31 Mar 202014.92%8.83
15 Apr 202015.33%8.36
30 Apr 202015.38%16.74
15 May 202015.60%13.6510-Q filed, results (8-K)
29 May 202014.83%12.03
15 Jun 202014.48%7.22
30 Jun 202016.30%11.22
15 Jul 202016.15%17.82
31 Jul 202016.06%24.57
14 Aug 202014.23%20.7710-Q filed, results (8-K)
31 Aug 202014.61%25.86
15 Sep 202014.88%14.85
30 Sep 202016.01%11.95
15 Oct 202017.13%19.23
30 Oct 202016.52%18.02
13 Nov 202016.36%21.8110-Q filed, results (8-K)
30 Nov 202016.50%22.89
15 Dec 202014.99%6.34
31 Dec 202012.66%11.81

See also: Fate Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.